Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A women-focused matrix mentorship programme in gastroenterology.
Devi J, Hutchins K, Sears D, Afzali A, Charabaty A. Devi J, et al. Among authors: afzali a. Lancet Gastroenterol Hepatol. 2024 May;9(5):405-407. doi: 10.1016/S2468-1253(23)00447-8. Lancet Gastroenterol Hepatol. 2024. PMID: 38604193 No abstract available.
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Sands BE, D'Haens G, Panaccione R, Regueiro M, Ghosh S, Hudesman D, Ahmad HA, Mehra D, Wu H, Jain A, Petersen A, Osterman MT, Afzali A, Danese S. Sands BE, et al. Among authors: afzali a. Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00405-1. doi: 10.1016/j.cgh.2024.03.042. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38723981 Free article.
Indications and safety of newer IBD treatments in the older patient.
Clement B, De Felice K, Afzali A. Clement B, et al. Among authors: afzali a. Curr Gastroenterol Rep. 2023 Jul;25(7):160-168. doi: 10.1007/s11894-023-00874-9. Epub 2023 May 25. Curr Gastroenterol Rep. 2023. PMID: 37227615 Free PMC article. Review.
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, Afzali A, Wolf DC, Chiorean MV, Vermeire S, Jain A, Charles L, Lawlor G, Osterman MT, Wu H, Canavan JB, Petersen A, Colombel JF, Regueiro M. Danese S, et al. Among authors: afzali a. J Crohns Colitis. 2024 Feb 26;18(2):264-274. doi: 10.1093/ecco-jcc/jjad146. J Crohns Colitis. 2024. PMID: 37651686 Free PMC article. Clinical Trial.
Surgery for Crohn's Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts.
Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht A, Brensinger CM, Wu GD, Bittinger K; DINE-CD; SPARC IBD Investigators. Lewis JD, et al. Cell Mol Gastroenterol Hepatol. 2024 May 14:S2352-345X(24)00111-5. doi: 10.1016/j.jcmgh.2024.05.005. Online ahead of print. Cell Mol Gastroenterol Hepatol. 2024. PMID: 38750900 Free article.
Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry.
Herfarth HH, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti GG, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Long MD. Herfarth HH, et al. Among authors: afzali a. Clin Transl Gastroenterol. 2024 Mar 1;15(3):e00669. doi: 10.14309/ctg.0000000000000669. Clin Transl Gastroenterol. 2024. PMID: 38131617 Free PMC article.
118 results